SXTP: 60 Degrees Pharmaceuticals Inc. Company Short-Term Debt

Symbol and logo of brand 60 Degrees Pharmaceuticals (SXTP)

60 Degrees Pharmaceuticals (SXTP) specializes in developing medications for tropical diseases, generating revenue by supplying malaria treatments to the military and tourists. This price chart on the GURU.Markets platform demonstrates a metric at 0.00. Operations are complicated by a dependence on Asian raw materials and sanction risks associated with global distribution. Due to its early stage of development, the business requires investment as it faces a shortage of working capital.

SXTP (60degreespharma.com) Company Short-Term Debts history from 02/21/2024 to 10/31/2026

Metric breakdowns and analytics for 60 Degrees Pharmaceuticals Inc. (SXTP)

- current quotes and average value forecast:
Price Chart 60 Degrees Pharma|SXTP - Fair Value Consensus
- market capitalization information:
Market Value 60 Degrees Pharmaceuticals, Inc.|SXTP - Real Price to Acquire Entire Company
- shareholders' equity book value data:
Book Value per Share 60 Degrees Pharmaceuticals|SXTP - Book Capitalization|Market Cap to Net Assets Ratio 60degreespharma.com|SXTP - Aggregate Asset Value
- debt and liquidity data:
Total Debt to Capital 60 Degrees Pharmaceuticals|SXTP - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity 60 Degrees Pharma|SXTP - Company Aggregate Debt|Debts to Book Capitalization 60 Degrees Pharmaceuticals, Inc.|SXTP - Long-Term Liabilities|Company Short-Term Debts 60 Degrees Pharmaceuticals|Quick Ratio 60degreespharma.com
- net income and valuation multiples indicators:
SXTP - Net Income
Fundamental valuation:60degreespharma.com (SXTP)
Manufactured products of 60 Degrees Pharma

Liquidity control for 60 Degrees Pharmaceuticals (SXTP) is critical, as the costs of clinical trials for malaria drugs require strict capital management to minimize risks. By analyzing short-term borrowing levels, an investor assesses the total liabilities maturing within one year, which allows for the identification of hidden financial vulnerabilities and protects the portfolio from sharp drawdowns in the event of excessive debt growth.

Key competitors

SMMT - Company Short-Term Debt|Company Short-Term Loans and Borrowings MRNA (Moderna Inc)|Vaxcyte Corp (PCVX) - Company Short-Term Debt|Company Current Liabilities Tarsus Corp|CRMD (CorMedix Inc.) - Company Short-Term Debts|Company Short-Term Debts serestherapeutics.com|Company Current Liabilities SPRO (Spero Therapeutics, Inc.)|SCYX (scynexis.com) - Company Short-Term Loans and Borrowings|Company Short-Term Debts ANTX (AN2 Therapeutics)|Short-Term Debt Volume PolyPid Ltd (PYPD)|LSB - Company Short-Term Debt|ITRM (Iterum Therapeutics plc) - Company Short-Term Indebtedness|PHGE: Company Short-Term Debts|Current Liabilities SNGX (Soligenix)|OGEN (Oragenics, Inc.) - Company Short-Term Debts|Short-Term Debt Onconetix Corporation ONCO|Company Short-Term Debts OPGN